As part of its ongoing commitment to accelerating cancer innovation and assembling tools to fight the disease, GE Healthcare, a unit of General Electric Company (NYSE: GE), will highlight the benefits of the company’s broad portfolio of advanced cancer treatment solutions at the 2013 Radiological Society of North America (#RSNA13) annual meeting. GE’s innovations, including Positron Emission Tomography (PET), Molecular Breast Imaging (MBI) and Automated Whole Breast Ultrasound System (ABUS) diagnostic imaging procedures, provide clinicians with improved tools to better detect cancer and monitor therapy. These breakthrough offerings are in the spirit of GE Healthcare’s $1 billion commitment to fight cancer.
delivers both PET quantitation and image quality
Clinicians will soon have a tool to quickly and confidently evaluate a patient’s response to cancer treatment utilizing Q.Clear, which provides up to two times improvement in both PET quantitative accuracy (SUV
) and image quality (signal-to-noise ratio). Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare’s new 510(k)-pending Q.Clear technology on display at RSNA, shows the advantage of full convergence PET imaging without compromise between quantitation and image quality.
“We know that cancer patients don’t always respond to their initial course of treatment,” said Steve Gray, president and CEO of GE Healthcare’s Molecular Imaging and CT business. “If we can give clinicians a more accurate, reliable and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/CT can help clinicians determine whether chemotherapy is working after as few as one to two cycles, saving patients unnecessary procedures and a significant amount of money. Q.Clear gives clinicians the ability to help make that determination.”